PKMYT1 promoted the growth and motility of hepatocellular carcinoma cells by activating beta-catenin/TCF signaling

Liu, Lei; Wu, Jinsheng; Wang, Shaochuang; Luo, Xi; Du, Yemu; Huang, Dongfang; Gu, Dianhua; Zhang, Feng

doi:10.1016/j.yexcr.2017.06.014

Cited by 36 publications

(36 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well-established that CDK1 is a key molecule in the progression of mitosis, and thus PKMYT1 is thought to play important roles in the regulation of the cell cycle and tumor biology (Parker and Piwnica-Worms, 1992). PKMYT1 is a crucial promoter in the development of hepatocellular carcinoma (Aguiar et al, 2017;Liu et al, 2017), and overexpression of PKMYT1 indicates a poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer (Sun et al, 2019). Currently the functional significance of PKMYT1 in prostate cancer remains unclear, and it makes sense to determine whether PKYMT1 is indispensable in prostate cancer, which requires further investigation.…”

Section: Discussionmentioning

confidence: 99%

Integrative Analysis of MicroRNA and Gene Interactions for Revealing Candidate Signatures in Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

MicroRNA (miRNA)-gene interactions are well-recognized as involved in the progression of almost all cancer types including prostate cancer, which is one of the most common cancers in men. This study explored the significantly dysregulated genes and miRNAs and elucidated the potential miRNA-gene regulatory network in prostate cancer. Integrative analysis of prostate cancer and normal prostate transcriptomic data in The Cancer Genome Atlas dataset was conducted using both differential expression analysis and weighted correlation network analysis (WGCNA). Thirteen genes (RRM2,

show abstract

Section: Discussionmentioning

confidence: 99%

Integrative Analysis of MicroRNA and Gene Interactions for Revealing Candidate Signatures in Prostate Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Epithelial-mesenchymal transition (EMT), an important process in tumor progression, is involved in several aspects including invasion, metastasis and drug resistance (27)(28)(29)(30)(31)(32)(33)(34). In hepatocellular carcinoma cells, PKMYT1 has been shown to regulate EMT by activating beta-catenin/TCF signaling (35). In the present study, we also found that depletion of PKMYT1 impaired the mobility of CRC cells, a function that is related to EMT, proposing that PKMYT1 was an essential molecule in the progression of CRC.…”

Section: Discussionmentioning

confidence: 99%

Protein kinase, membrane‑associated tyrosine/threonineï¿½1 is associated with the progression of colorectal cancer

Jeong

Kim

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

The protein kinase, membrane‑associated tyrosine/threonine 1 (PKMYT1) is known to inhibit precocious entry into mitosis by phosphorylating CDK1 at Thr14 and Tyr15 residues. However, the functional importance of PKMYT1 in colorectal cancer (CRC) remains unknown. Thus, it is important to elucidate whether PKYMT1 is indispensable in the tumorigenesis of CRC. To investigate the functional importance of PKMYT1 in CRC tumorigenesis, PKMYT1 was knocked down in CRC cell lines such as SW480, SW620, HCT116 and HT29 by siRNA. PKMYT1‑depleted CRC cells were analyzed to determine proliferation, migration, invasion and colony forming ability. In addition, 179 patient‑derived samples were used to find the correlation of the expression of PKMYT1 with the prognosis of CRC patients. By siRNA‑mediated loss of function of PKMYT1, we observed that proliferation, migration, invasion and colony forming ability of CRC cell lines were significantly impaired in the absence of PKMYT1 in vitro. Furthermore, by analyzing patient‑derived samples, we revealed the association of PKMYT1 with the overall survival rate of CRC patients. These results indicated that PKMYT1 plays an essential oncogenic role in CRC and could serve as a good therapeutic target for the treatment of CRC.

show abstract

“…In melanoma cells, WEE1 silencing caused an increase of phospho p38 protein levels, indicating a role in the regulation of p38/MAPK pathway activation during p53-independent DNA damage response [ 49 ]. In hepatocellular carcinoma and colorectal cancers, PKMYT1 regulates epithelial-mesenchymal transition (EMT), a process relevant to tumor progression, invasion, metastasis, and drug resistance, through the activation of the beta-catenin/TCF signaling [ 32 , 46 ], while PKMYT1 has been reported to control Notch pathway in NSCLC [ 45 ]. In particular, crucial component of the pathway, including NOTCH1, p21, and HES1 are downregulated by chemical inhibition of PKMYT1 [ 45 ].…”

Section: Wee1 and Pkmyt1 Deregulation In Cancer Cellsmentioning

confidence: 99%

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

et al. 2020

View full text Add to dashboard Cite

The inhibition of the DNA damage response (DDR) pathway in the treatment of cancer has recently gained interest, and different DDR inhibitors have been developed. Among them, the most promising ones target the WEE1 kinase family, which has a crucial role in cell cycle regulation and DNA damage identification and repair in both nonmalignant and cancer cells. This review recapitulates and discusses the most recent findings on the biological function of WEE1/PKMYT1 during the cell cycle and in the DNA damage repair, with a focus on their dual role as tumor suppressors in nonmalignant cells and pseudo-oncogenes in cancer cells. We here report the available data on the molecular and functional alterations of WEE1/PKMYT1 kinases in both hematological and solid tumors. Moreover, we summarize the preclinical information on 36 chemo/radiotherapy agents, and in particular their effect on cell cycle checkpoints and on the cellular WEE1/PKMYT1-dependent response. Finally, this review outlines the most important pre-clinical and clinical data available on the efficacy of WEE1/PKMYT1 inhibitors in monotherapy and in combination with chemo/radiotherapy agents or with other selective inhibitors currently used or under evaluation for the treatment of cancer patients.

show abstract

PKMYT1 promoted the growth and motility of hepatocellular carcinoma cells by activating beta-catenin/TCF signaling

Cited by 36 publications

References 13 publications

Integrative Analysis of MicroRNA and Gene Interactions for Revealing Candidate Signatures in Prostate Cancer

Integrative Analysis of MicroRNA and Gene Interactions for Revealing Candidate Signatures in Prostate Cancer

Protein kinase, membrane‑associated tyrosine/threonineï¿½1 is associated with the progression of colorectal cancer

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

Contact Info

Product

Resources

About